Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates

Courtney Woolsey, Joan B. Geisbert, Demetrius Matassov, Krystle N. Agans, Viktoriya Borisevich, Robert Cross, Daniel J. Deer, Karla A. Fenton, John H. Eldridge, Chad Mire, Thomas Geisbert

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20-30 minutes after exposure. A total of 25% and 60%-75% of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed.

Original languageEnglish (US)
Pages (from-to)S582-S587
JournalThe Journal of infectious diseases
Volume218
Issue number5
DOIs
StatePublished - Nov 22 2018

Fingerprint

Marburgvirus
Angola
Vesicular Stomatitis
Primates
Macaca
Viruses
Glycoproteins
Disease Progression
Vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates. / Woolsey, Courtney; Geisbert, Joan B.; Matassov, Demetrius; Agans, Krystle N.; Borisevich, Viktoriya; Cross, Robert; Deer, Daniel J.; Fenton, Karla A.; Eldridge, John H.; Mire, Chad; Geisbert, Thomas.

In: The Journal of infectious diseases, Vol. 218, No. 5, 22.11.2018, p. S582-S587.

Research output: Contribution to journalArticle

Woolsey, Courtney ; Geisbert, Joan B. ; Matassov, Demetrius ; Agans, Krystle N. ; Borisevich, Viktoriya ; Cross, Robert ; Deer, Daniel J. ; Fenton, Karla A. ; Eldridge, John H. ; Mire, Chad ; Geisbert, Thomas. / Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates. In: The Journal of infectious diseases. 2018 ; Vol. 218, No. 5. pp. S582-S587.
@article{85006f6c511f4a03990541272cdd6d9c,
title = "Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates",
abstract = "A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20-30 minutes after exposure. A total of 25{\%} and 60{\%}-75{\%} of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed.",
author = "Courtney Woolsey and Geisbert, {Joan B.} and Demetrius Matassov and Agans, {Krystle N.} and Viktoriya Borisevich and Robert Cross and Deer, {Daniel J.} and Fenton, {Karla A.} and Eldridge, {John H.} and Chad Mire and Thomas Geisbert",
year = "2018",
month = "11",
day = "22",
doi = "10.1093/infdis/jiy293",
language = "English (US)",
volume = "218",
pages = "S582--S587",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates

AU - Woolsey, Courtney

AU - Geisbert, Joan B.

AU - Matassov, Demetrius

AU - Agans, Krystle N.

AU - Borisevich, Viktoriya

AU - Cross, Robert

AU - Deer, Daniel J.

AU - Fenton, Karla A.

AU - Eldridge, John H.

AU - Mire, Chad

AU - Geisbert, Thomas

PY - 2018/11/22

Y1 - 2018/11/22

N2 - A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20-30 minutes after exposure. A total of 25% and 60%-75% of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed.

AB - A recombinant vesicular stomatitis virus (rVSV) expressing the Marburg virus (MARV) Musoke variant glycoprotein fully protects macaques against 2 MARV variants and Ravn virus as a preventive vaccine and MARV variant Musoke as a postexposure treatment. To evaluate postexposure efficacy against the most pathogenic MARV variant, Angola, we engineered rVSVs expressing homologous Angola glycoprotein. Macaques were challenged with high or low doses of variant Angola and treated 20-30 minutes after exposure. A total of 25% and 60%-75% of treated macaques survived the high-dose and low-dose challenges, respectively. The more rapid disease progression of variant Angola versus variant Musoke may account for the incomplete protection observed.

UR - http://www.scopus.com/inward/record.url?scp=85057168552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057168552&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiy293

DO - 10.1093/infdis/jiy293

M3 - Article

C2 - 29939296

AN - SCOPUS:85057168552

VL - 218

SP - S582-S587

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -